Interventional

Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes.

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of SOS. Romeo S, Maglio C, Burza CA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;32:2613-2617. The Swedish Obese Subjects (SOS) study is a nonrandomized, controlled, prospective interventional trial that compares the effects of bariatric surgery and usual care on morbidity and mortality outcomes.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Health benefits of gastric bypass surgery after 6 years

Top

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122-1131. This prospective study by Adams and colleagues explored the weight loss and cardiometabolic benefits of Roux-en-Y gastric bypass (RYGB) among severely obese patients over 6 years of follow-up.

Weight loss surgery for mild to moderate obesity: a systematic review and economic evaluation

Top

Picot J, Jones J, Colquitt JL, Loveman E, Clegg AJ. Weight loss surgery for mild to moderate obesity a systematic review and economic evaluation. Obes Surg. 2012;22(9):1496-1506. A systematic review and economic evaluation was commissioned to determine the effectiveness and cost-effectiveness of bariatric surgery for mild [class I, body mass index (BMI) 30 to 34.99] or moderate (class II, BMI 35 to 39.99) obesity.

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

Top

Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695-704. The Swedish Obese Subjects (SOS) study compared the long-term effects of bariatric surgery with the effects of usual care for type 2 diabetes prevention among 3,429 subjects with obesity.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.

Ethnic Differences in Weight Loss and Diabetes Remission After Bariatric Surgery: A meta-analysis

Top

Admiraal WM, Celik F, Gerdes VE, Dallal RM, Hoekstra JB, Holleman F. Ethnic Differences in Weight Loss and Diabetes Remission After Bariatric Surgery A meta analysis. Diabetes Care. 2012;35(9):1951-1958. It has been postulated that the effectiveness of bariatric surgery varies between ethnic groups. However, data regarding this topic are inconclusive, as most studies included few patients from minority groups.

Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients

Top

Mukerji R, Petruc M, Fresen JL, Terry BE, Govindarajan G, Alpert MA. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol. 2012;110(3):415-419. To assess the effect of weight loss on ventricular repolarization in morbidly obese patients, 39 normotensive subjects whose baseline body mass indexes were ≥40 kg/m2 before weight loss from bariatric surgery were studied.

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

1 2 3 4 5 6 7 Next